SYHA1813 + paclitaxel

SYHA1813 + paclitaxel is an experimental combination therapy investigated for the treatment of malignant tumors. **SYHA1813** is a novel, investigational, small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), developed primarily for antitumor activity in cancers characterized by dysregulated FGFR4 signaling. **Paclitaxel** is an approved antineoplastic agent widely utilized in multiple cancer types including breast, ovarian, and lung cancer. Paclitaxel acts as a microtubule stabilizer, disrupting mitosis and inducing apoptosis by binding to β-tubulin and preventing microtubule depolymerization[1][2][4][8]. The combination is under clinical investigation for possible synergistic or additive effects in tumor inhibition.

Brand names

Abraxane